Gastroenterology & Hepatology · page 3

Naltrexone tripled abstinence in compensated alcohol-associated cirrhosis without hepatic harm

A randomised trial in 100 patients with compensated alcohol-related cirrhosis and alcohol use disorder found 64% abstinent at twelve weeks on naltrexone against 22% on placebo, with no decompensation attributable to the drug and no transaminase rise beyond five times normal in either arm.